Morphic Therapeutic (MORF) stock price, revenue, and financials
Morphic Therapeutic market cap is $500.5 m, and annual revenue was $3.36 m in FY 2019
$15.34
$500.5 M
MORF Mkt cap, 10-Dec-2019$3.4 M
Morphic Therapeutic Revenue FY, 2019Morphic Therapeutic Net income (FY, 2019)-23.8 M
Morphic Therapeutic EBIT (FY, 2019)-24.6 M
Morphic Therapeutic Cash, 30-Sept-2019159.8 M
Morphic Therapeutic Income Statement
Annual
Morphic Therapeutic Balance Sheet
Annual
| USD | FY, 2017 | FY, 2018 |
|---|---|---|
Cash | 20.8m | 185.9m |
Prepaid Expenses | 479.0k | 1.2m |
Current Assets | 21.2m | 187.1m |
PP&E | 1.7m | 1.8m |
Total Assets | 23.2m | 189.3m |
Accounts Payable | 883.0k | 1.7m |
Short-term debt | 315.0k | |
Current Liabilities | 2.5m | 34.9m |
Long-term debt | 315.0k | |
Total Debt | 630.0k | |
Total Liabilities | 3.2m | 102.0m |
Preferred Stock | 49.7m | 139.8m |
Additional Paid-in Capital | 661.0k | 1.6m |
Total Equity | 20.0m | 87.3m |
Financial Leverage | 1.2 x | 2.2 x |
Quarterly
| USD | Q2, 2019 | Q3, 2019 |
|---|---|---|
Cash | 44.2m | 159.8m |
Accounts Receivable | 945.0k | 2.4m |
Prepaid Expenses | 1.4m | 2.9m |
Current Assets | 172.8m | 257.0m |
PP&E | 2.5m | 2.7m |
Total Assets | 178.6m | 260.1m |
Accounts Payable | 2.9m | 3.3m |
Current Liabilities | 43.5m | 26.5m |
Total Liabilities | 104.8m | 100.7m |
Common Stock | 3.0k | |
Additional Paid-in Capital | 2.8m | 237.0m |
Retained Earnings | (68.8m) | (77.7m) |
Total Equity | (66.0m) | 159.3m |
Financial Leverage | -2.7 x | 1.6 x |
Morphic Therapeutic Cash Flow
Annual
| USD | FY, 2017 | FY, 2018 |
|---|---|---|
Net Income | (16.9m) | (23.8m) |
Depreciation and Amortization | 434.0k | 539.0k |
Accounts Payable | 285.0k | 862.0k |
Cash From Operating Activities | (15.4m) | 7.6m |
Purchases of PP&E | (945.0k) | (659.0k) |
Cash From Investing Activities | (907.0k) | (656.0k) |
Long-term Borrowings | (333.0k) | (652.0k) |
Cash From Financing Activities | 2.0m | 89.5m |
Net Change in Cash | 3.9m | 165.2m |
Interest Paid | 31.0k | 68.0k |
Quarterly
| USD | Q2, 2019 | Q3, 2019 |
|---|---|---|
Net Income | (14.6m) | (23.5m) |
Depreciation and Amortization | 365.0k | 576.0k |
Accounts Receivable | (945.0k) | (2.4m) |
Accounts Payable | 1.2m | 1.5m |
Cash From Operating Activities | (13.9m) | (27.6m) |
Purchases of PP&E | (1.1m) | (1.4m) |
Cash From Investing Activities | (126.0m) | (91.8m) |
Cash From Financing Activities | (1.8m) | 93.3m |
Net Change in Cash | (141.7m) | (26.1m) |
Income Taxes Paid | 550.0k |
Morphic Therapeutic Ratios
| USD | Y, 2019 |
|---|---|
Revenue/Employee | 51.4k |
Financial Leverage | 1.6 x |
